Chief Financial Officer · SOPHiA GENETICS SA · Ordinary Shares
Open-market sale
$13K reported value · 0.5% of prior position
Disclosed 2 business days after execution (deadline: 2)
Routine: 8 prior trades recorded in this security
8 other actors traded the same direction within 14 days
No material company filing within 60 days after the trade
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 13 | Menu PhilippeChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $36K 5,000 sh | Oct 14, 2026 traded Oct 12, 2026 | |
| 16 | Camblong JurgiDirector, Executive Chairman | Open-market sale · 10b5-1 plan | SELL | $62K 8,500 sh | Oct 14, 2026 traded Oct 12, 2026 | |
| 13 | Xu ZhenyuChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $29K 4,000 sh | Oct 14, 2026 traded Oct 13, 2026 | |
| 16 | Menu PhilippeChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $60K 7,394 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 29 | Puylaert KevinChief Sales Officer | Open-market sale | SELL | $1,491 185 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 29 | Puylaert KevinChief Sales Officer | Open-market sale | SELL | $246 31 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 16 | Van Well DaanChief Legal Officer | Open-market sale · 10b5-1 plan | SELL | $50K 6,168 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 16 | Xu ZhenyuChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $60K 7,394 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 16 | Muken RossDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $80K 9,838 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 13 | Verma AbhimanyuChief Technology Officer | Open-market sale · 10b5-1 plan | SELL | $43K 5,284 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 13 | Valente ManuelaChief People Officer | Open-market sale · 10b5-1 plan | SELL | $34K 4,240 sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 19 | Camblong JurgiDirector, Executive Chairman | Open-market sale · 10b5-1 plan | SELL | $327K 40.2K sh | Oct 7, 2026 traded Oct 5, 2026 | |
| 13 | Muken RossDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $3,515 422 sh | Sep 22, 2026 traded Sep 21, 2026 | |
| 13 | Cardoza GeorgeChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $6,447 774 sh | Sep 22, 2026 traded Sep 21, 2026 | |
| 29 | Menu PhilippeChief Medical Officer | Open-market sale | SELL | $39K 5,000 sh | Sep 16, 2026 traded Sep 14, 2026 | |
| 13 | Xu ZhenyuChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $32K 4,000 sh | Sep 16, 2026 traded Sep 14, 2026 | |
| 16 | Camblong JurgiDirector, Executive Chairman | Open-market sale · 10b5-1 plan | SELL | $65K 8,500 sh | Sep 14, 2026 traded Sep 10, 2026 | |
| 13 | Van Well DaanChief Legal Officer | Open-market sale · 10b5-1 plan | SELL | $47K 6,168 sh | Sep 14, 2026 traded Sep 11, 2026 | |
| 23 | Hibbs Kathy LDirector | Open-market sale · 10b5-1 plan | SELL | $51K 6,250 sh | Sep 10, 2026 traded Sep 8, 2026 | |
| 16 | Xu ZhenyuChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $89K 10.0K sh | Aug 31, 2026 traded Aug 27, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $12,897
Cardoza George filed this Form 4 reporting a open-market sale of SOPH on Oct 5, 2026. It became public on Oct 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.